0809 GMT - Smith & Nephew's continuing strength in U.S. orthopedics is reassuring, RBC Capital Markets analyst Jack Reynolds-Clark says in a research note. The U.K. medical-technology company posted first-quarter revenue in line with consensus expectations, with underlying growth ahead of views albeit a greater-than-expected impact of currency fluctuations, the analyst says. As expected, the performance in China was a significant headwind in the quarter, the analyst adds. "The results demonstrate continued strength in U.S. Orthopaedics and Sports Medicine and incrementally de-risk expectations for the full year 2025," the analyst says. Shares are up 5.1% at 1,050.50 pence. (maitane.sardon@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 04:09 ET (08:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。